Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury
/ScienceDirect/2026
Why It Matters
This paper caught my attention because nerve injuries are notoriously slow to heal, and BPC 157 keeps popping up in biohacking circles with bold claims. The catch? This is purely animal data — no human trials. If you're considering peptide therapy for nerve damage, understand you'd be experimenting based on rat studies, not clinical evidence.
Key Findings
- BPC 157 demonstrated neuroprotective effects in rat models of traumatic peripheral nerve injury
- Treatment appeared to accelerate functional recovery after nerve damage in animal studies
- The peptide showed potential to support nerve regeneration processes in preclinical models
- No human safety or efficacy data exists — all findings are from animal experiments
- Mechanism of action remains incompletely understood even in animal models